Table 1.
Sociodemographic, clinical and treatment characteristics for each of the dose interval groups
| Low-dose interval, n = 3455 | Medium-dose interval, n = 2430 | High-dose interval, n = 2032 | P-value | |
|---|---|---|---|---|
| Mean (s.d.) or n (%) | Mean (s.d.) or n (%) | Mean (s.d.) or n (%) | ||
| Age, years | 53.7 (19.3) | 53.7 (18.4) | 51.5 (18.1) | <0.001 |
| Gender | ||||
| Female | 2026 (58.6%) | 1511 (62.2%) | 1054 (51.9%) | <0.001 |
| Male | 1429 (41.4%) | 919 (37.8%) | 978 (48.1%) | |
| Anxiety disorder | 859 (24.9%) | 619 (25.5%) | 569 (28.0%) | 0.033 |
| Personality Disorder | 223 (6.5%) | 170 (7.0%) | 144 (7.1%) | 0.588 |
| Substance misuse | 320 (9.3%) | 274 (11.3%) | 282 (13.9%) | <0.001 |
| COPD | 50 (1.4%) | 28 (1.2%) | 22 (1.1%) | 0.426 |
| Diabetes type 2 | 129 (3.7%) | 107 (4.4%) | 72 (3.5%) | 0.274 |
| Heart disease | 99 (2.9%) | 65 (2.7%) | 39 (1.9%) | 0.093 |
| Kidney failure | 26 (0.8%) | 14 (0.6%) | 8 (0.4%) | 0.248 |
| Antidepressants | 2665 (77.1%) | 1973 (81.2%) | 1675 (82.4%) | <0.001 |
| Anti-epileptics | 231 (6.7%) | 223 (9.2%) | 197 (9.7%) | <0.001 |
| Antipsychotics | 1174 (34.0%) | 887 (36.5%) | 763 (37.5%) | 0.017 |
| Benzodiazepines | 1513 (43.8%) | 1135 (46.7%) | 964 (47.4%) | 0.014 |
| Lithium | 173 (5.0%) | 133 (5.5%) | 132 (6.5%) | 0.066 |
| Severity | ||||
| CGI-S before | 5.3 (0.8) | 5.2 (0.9) | 5.0 (0.9) | <0.001 |
| MADRS-S before | 33.7 (9.3) | 34 (9.0) | 33.7 (8.6) | 0.447 |
P-values were calculated using one-way ANOVA for mean and Pearson chi-squared for proportions. COPD, chronic obstructive pulmonary disease; CGI-S, Clinical Global Impression – Severity Scale, MADRS-S, Montgomery–Åsberg Depression Rating Scale, self-rated version.